These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34844712)

  • 41. Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers.
    Namba S; Saito Y; Kogure Y; Masuda T; Bondy ML; Gharahkhani P; Gockel I; Heider D; Hillmer A; Jankowski J; MacGregor S; Maj C; Melin B; Ostrom QT; Palles C; Schumacher J; Tomlinson I; Whiteman DC; Okada Y; Kataoka K
    Cancer Res; 2023 Jan; 83(1):20-27. PubMed ID: 36286845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL; Szymaniak BM; Numan Y; Morgans AK
    Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline BRCA mutation in male carriers-ripe for precision oncology?
    Leão RRN; Price AJ; James Hamilton R
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
    Dhawan M; Ryan CJ
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.
    Cheng HH; Klemfuss N; Montgomery B; Higano CS; Schweizer MT; Mostaghel EA; McFerrin LG; Yu EY; Nelson PS; Pritchard CC
    Prostate; 2016 Oct; 76(14):1303-11. PubMed ID: 27324988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
    Ruan X; Huang D; Huang J; Tsu JH; Na R
    J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A genetic-based approach to personalized prostate cancer screening and treatment.
    Helfand BT; Catalona WJ; Xu J
    Curr Opin Urol; 2015 Jan; 25(1):53-8. PubMed ID: 25405931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Germline testing in those at risk of prostate cancer.
    Carroll PR; Witte JS; Parsons JK
    Can J Urol; 2019 Oct; 26(5 Suppl 2):31-33. PubMed ID: 31629425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ethnic disparities among men with prostate cancer undergoing germline testing.
    Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
    Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).
    Benafif S; Kote-Jarai Z; Eeles RA;
    Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):845-857. PubMed ID: 29348298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    Paller CJ; Antonarakis ES; Beer TM; Borno HT; Carlo MI; George DJ; Graff JN; Gupta S; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Petrylak DP; Rettig MB; Ryan CJ; Taplin ME; Whang YE; Vinson J; Cheng HH; Giri VN;
    Clin Genitourin Cancer; 2019 Aug; 17(4):275-282.e1. PubMed ID: 31171481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hereditary prostate cancer - Primetime for genetic testing?
    Heidegger I; Tsaur I; Borgmann H; Surcel C; Kretschmer A; Mathieu R; Visschere P; Valerio M; van den Bergh RCN; Ost P; Tilki D; Gandaglia G; Ploussard G;
    Cancer Treat Rev; 2019 Dec; 81():101927. PubMed ID: 31783313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring the Germline Genetics of In Situ and Invasive Cutaneous Melanoma: A Genome-Wide Association Study Meta-Analysis.
    Ingold N; Seviiri M; Ong JS; Neale RE; Pandeya N; Whiteman DC; Olsen CM; Martin NG; Duffy DL; Khosrotehrani K; Hayward N; Montgomery GW; MacGregor S; Law MH
    JAMA Dermatol; 2024 Sep; 160(9):964-971. PubMed ID: 39141363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.